Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell therapy company StemCyte has reported the formation of a joint venture in India with Apollo Hospitals and Cadila Pharmaceuticals.
Subscribe to our email newsletter
The joint-venture company, StemCyte India Therapeutics, will provide stem cell therapies derived from umbilical cord blood to treat patients with certain malignant blood disorders, including leukemia, lymphoma, myeloma and inherited disorders such as sickle cell anemia and thalassemia and immune deficiency diseases.
In addition, StemCyte India Therapeutics will participate in clinical studies to develop cell therapies for indications for which there are unmet clinical needs.
Kenneth Giacin, chairman and CEO of StemCyte, said: “The joint venture enables us to combine StemCyte’s proven cell therapy products with Apollo and Cadila’s expertise in the Indian healthcare market for the benefit of one of the largest patient populations in the world. Furthermore, StemCyte India Therapeutics is an important part of our global expansion strategy.”